Bafna Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
BAFNAPH
Pharmaceuticals
Screen Bafna Pharmaceuticals share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹118.01
▼
-4.95 (-4.03%)
Share Price BSE
₹146.90
▼
-7.70 (-4.98%)
Market Cap
₹344.29 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
7.16
EPS (TTM)
₹-15.52
Dividend Yield
-
Debt to Equity
0.70
52W High
₹122.96
52W Low
₹70.97
Operating Margin
-42.00%
Profit Margin
-28.57%
Revenue (TTM)
₹7.00
EBITDA
₹-3.00
Net Income
₹-2.00
Total Assets
₹71.00
Total Equity
₹51.00
Bafna Pharmaceuticals Share Price History - Stock Screener Chart
Screen BAFNAPH historical share price movements with interactive charts. Analyze price trends and patterns.
Bafna Pharmaceuticals Company Profile - Fundamental Screener
Screen Bafna Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for BAFNAPH shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE878I01022
Bafna Pharmaceuticals Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen BAFNAPH balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|
| Assets | ||||||
| Total Assets | 71 | 120 | 138 | 178 | 193 | 200 |
| Current Assets | 36 | 49 | 49 | 77 | 123 | 127 |
| Fixed Assets | 35 | 37 | 45 | 49 | 53 | 55 |
| Liabilities | ||||||
| Total Liabilities | 71 | 120 | 138 | 178 | 193 | 200 |
| Current Liabilities | 3 | 30 | 41 | 55 | 40 | 16 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||
| Total Equity | 51 | 19 | 37 | 42 | 58 | 73 |
| Share Capital | 2 | 24 | 24 | 19 | 19 | 19 |
| Reserves & Surplus | -7 | -5 | 14 | 20 | 39 | 53 |
Screen BAFNAPH income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2019-Jun | 2019-Sept | 2018-Jun | 2018-Sept |
|---|---|---|---|---|
| Revenue | 7 | 12 | 12 | 9 |
| Expenses | 10 | 12 | 14 | 9 |
| EBITDA | -3 | 0 | -2 | 0 |
| Operating Profit % | -42.00% | -3.00% | -15.00% | 2.00% |
| Depreciation | 1 | 1 | 1 | 1 |
| Interest | 0 | 0 | 1 | 1 |
| Profit Before Tax | -4 | -1 | -4 | -1 |
| Tax | -2 | 0 | 0 | 0 |
| Net Profit | -2 | -1 | -4 | -1 |
| EPS | -0.90 | -0.25 | 0.00 | -0.80 |
Bafna Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen BAFNAPH cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|
| Operating Activities | -34 | -2 | -7 | -1 | 1 | 11 |
| Investing Activities | 33 | 15 | 38 | -5 | 0 | 60 |
| Financing Activities | 7 | -14 | -31 | 6 | -1 | -71 |
| Net Cash Flow | 6 | 0 | 0 | 0 | 0 | 0 |
Screen BAFNAPH shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 75.00% | 75.00% | 75.00% | 88.30% | 88.30% | 88.30% | 88.30% | 88.43% |
| FII Holding | 9.34% | 9.34% | 8.53% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 12.03% | 11.62% | 11.06% | 7.66% | 7.69% | 7.37% | 7.48% | 7.66% |
| Other Holding | 3.63% | 4.04% | 5.40% | 4.04% | 4.01% | 4.34% | 4.23% | 3.91% |
| Shareholder Count | 7,572 | 7,283 | 7,142 | 7,214 | 7,295 | 7,391 | 7,539 | 7,367 |
Bafna Pharmaceuticals Dividend Screener - Share Yield Analysis
Screen BAFNAPH dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
Bafna Pharmaceuticals Index Membership - Market Screener Classification
Screen BAFNAPH by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Bafna Pharmaceuticals Market Events Screener - Corporate Actions
Screen BAFNAPH market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 43.07% | ||
| Annual General Meeting | NA | -2.66% | ||
| 2025-11-11 | 2025-11-11 | Quarterly Result Announcement | NA | 12.98% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | 10.01% |
| 2025-05-26 | 2025-05-26 | Quarterly Result Announcement | NA | -5.05% |
| 2025-02-06 | 2025-02-06 | Quarterly Result Announcement | NA | 0.76% |
| 2024-11-11 | 2024-11-11 | Quarterly Result Announcement | NA | 2.21% |
Bafna Pharmaceuticals Competitors Screener - Peer Comparison
Screen BAFNAPH competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 427,705 | 40.28 | 54,729 | 9.71% | 10,980 | 58.99 |
| Divis Laboratories | 176,338 | 70.98 | 9,712 | 18.67% | 2,191 | 63.15 |
| Torrent Pharmaceuticals | 138,499 | 62.26 | 11,539 | 6.99% | 1,911 | 80.95 |
| Cipla | 118,573 | 22.75 | 28,410 | 7.12% | 5,291 | 38.52 |
| Dr Reddys Laboratories | 103,728 | 18.27 | 33,741 | 16.73% | 5,725 | 40.17 |
| Lupin | 101,149 | 22.61 | 22,910 | 13.74% | 3,306 | 71.67 |
| Mankind Pharma | 95,432 | 52.17 | 12,744 | 20.90% | 2,007 | 64.16 |
| Zydus Life Science | 93,333 | 18.63 | 23,511 | 18.55% | 4,615 | 52.14 |
| Aurobindo Pharma | 71,752 | 20.91 | 32,346 | 9.43% | 3,484 | 61.25 |
| Alkem Laboratories | 69,425 | 28.04 | 13,458 | 3.70% | 2,216 | 63.97 |
Bafna Pharmaceuticals Company Announcements - News Screener
Screen BAFNAPH latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2025-12-26 | Closure of Trading Window | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-11 | Unaudited Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-11 | Board Meeting Outcome for Outcome For The Board Meeting Held On 11/11/2025 | View |
| 2025-11-06 | Board Meeting Intimation for Meeting Scheduled On November 11 2025 | View |
| 2025-10-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-09-26 | Closure of Trading Window | View |
| 2025-09-19 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-09-19 | Announcement under Regulation 30 (LODR)-Change in Directorate | View |
| 2025-09-19 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-08-28 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-26 | Notice Of 30Th Annual General Meeting Of The Company For The F.Y 2024-2025 | View |
| 2025-08-26 | Reg. 34 (1) Annual Report. | View |
| 2025-08-21 | Book Closure For 30Th Annual General Meeting (AGM) | View |
| 2025-08-21 | Shareholder Meeting - 30Th AGM On September 19 2025 | View |
| 2025-08-14 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-08-12 | Announcement under Regulation 30 (LODR)-Change in Directorate | View |
| 2025-08-12 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-08-12 | Unaudited Financial Results For The Quarter Ended June 30 2025 | View |
| 2025-08-12 | Board Meeting Outcome for Outcome For The Board Meeting Held On 12/08/2025 | View |